Treatment retention, drug-use outcomes improved with injectable form of naltrexone

2019 ◽  
Vol 30 (2) ◽  
pp. 1-6

2016 ◽  
Vol 47 (2) ◽  
pp. 148-163 ◽  
Author(s):  
Elizabeth A. Hall ◽  
Michael L. Prendergast ◽  
Umme Warda

This study was a randomized effectiveness trial of the use of incentives to improve treatment retention and post-treatment outcomes among parolees in community treatment. Parolees entering community treatment were randomized to incentives ( N = 104) or brief education ( N = 98). It was hypothesized that the use of incentives to increase treatment retention would result in improved post-treatment outcomes (i.e., arrest, employment, and drug use), but at 18 months post-intake, there were no group differences for any outcome. In secondary analyses, rearrest by 18 months post-intake was predicted by substance use, greater number or severity of psychological symptoms, treatment non-completion, unemployment, and younger age. Contrary to expectations, results indicated that participants who received incentives for attendance had arrest, employment, and drug use outcomes similar to those who received a brief education session. Our findings, in concert with those of several other researchers, suggest that there may be certain populations or settings where incentives may not be effective.



2003 ◽  
Vol 71 (5) ◽  
pp. 862-878 ◽  
Author(s):  
Paul C. Amrhein ◽  
William R. Miller ◽  
Carolina E. Yahne ◽  
Michael Palmer ◽  
Laura Fulcher




2020 ◽  
Vol 14 ◽  
pp. 117822182097092
Author(s):  
Nihit Kumar ◽  
Michael J Mancino ◽  
Jeff D Thostenson ◽  
Janette McGaugh ◽  
Alison H Oliveto

Background: Given the immense burden of the widespread use of opioids around the world, exploring treatments that improve drug use outcomes, and craving and withdrawal measures in individuals with opioid use disorder is crucial. This pilot study examined the feasibility and preliminary efficacy of the L-type calcium-channel blocker isradipine (ISR) to improve drug use outcomes, and craving and withdrawal measures during buprenorphine (BUP)/ISR stabilization and subsequent taper in opioid-dependent individuals. Methods: Participants were stabilized on BUP sublingual tablets within the first 2 days of week 1, were then randomized and inducted on either ISR or placebo, gradually increasing the dose over the next 2 weeks, followed by a 10-day BUP taper during weeks 5-6, and ISR/placebo taper during weeks 7 to 8. Assessments included thrice-weekly measures of craving and withdrawal, as well as vital signs and urine drug screens. Medication compliance was assessed by monitoring number of missed clinic visit days. Results: Baseline characteristics of participants (n = 25; 60% male, 96% Caucasian, 48% employed, mean age 32.8 years) did not differ significantly between treatment groups (isradipine, n = 11; placebo, n = 14). During the stabilization phase (n = 19), ISR participants had significantly lower rates of illicit opioid-positive urines (treatment × visit: t = -2.16, P = 0.03), as well as reduction in craving intensity ( t = –2.50, P = 0.01), frequency ( t = –3.43, P < 0.01) and duration ( t = –2.51, P = 0.01). ISR was well tolerated with mild adverse effects. Conclusions: This study was likely underpowered due to being a pilot trial. Although preliminary results suggest ISR may improve BUP-assisted treatment outcomes, concerns about high number of exclusions (n = 11 during taper phase) based on cardiovascular measures as well as ISR-induced changes in vital signs with the immediate release formulation may limit the feasibility of this approach. Trial Registration: Clinicaltrials.gov identifier NCT01895270. Registered 10 July 2013, https://clinicaltrials.gov/ct2/show/NCT01895270?id=NCT01895270&draw=2&rank=1





Author(s):  
Paolo Deluca ◽  
Zoe Davey ◽  
Ornella Corazza ◽  
Lucia Di Furia ◽  
Magi Farre ◽  
...  




2014 ◽  
Vol 46 (2) ◽  
pp. 114-122 ◽  
Author(s):  
William L. White ◽  
Michael D. Campbell ◽  
Robert D. Spencer ◽  
Howard A. Hoffman ◽  
Brian Crissman ◽  
...  


Sign in / Sign up

Export Citation Format

Share Document